News

Our systematic review examines urge urinary incontinence (UUI) in pregnancy. We identified several risk factors for UUI. A key finding is the literature's predominant focus on quantifying UUI symptoms ...
Overactive bladder (OAB) remains a prevalent and often debilitating syndrome, affecting millions worldwide. Despite numerous treatment options, including behavioral modifications, pharmacologic ...
Muscle-invasive bladder cancer (MIBC) presents significant treatment challenges, with antibody-drug conjugates (ADCs) targeting HER2, NECTIN4, and TROP-2 emerging as promising therapeutic options.
Background: Testicular seminomas, a common germ cell tumor, poses clinical challenges due to its molecular heterogeneity and limited biomarkers for precise diagnosis and prognosis. Leveraging ...
The World Health Organization/International Society of Urological Pathology (WHO/ISUP) grading of clear cell renal cell carcinoma (ccRCC) is crucial for prognosis and ...
This review explores challenges in managing biochemical recurrence (BCR) after radical prostatectomy and postoperative radiotherapy for prostate cancer (PCa) highlighting gaps in risk stratification, ...
To analyse postoperative outcomes after inguinal lymph node dissection (ILND) at a high-volume North American centre for penile cancer with respect to early postoperative clinic visits facilitated by ...
Castration and enzalutamide induce BCL-2 to drive therapy resistance in prostate cancer (PCa). We conducted a phase Ib trial to test that metastatic castration-resistant PCa (mCRPC) can be effectively ...
Invasive urodynamics (iUDS) should be selectively performed in male patients with lower urinary tract symptoms before invasive treatment for benign prostatic obstruction. Recent evidence highlights ...
Venous tumour thrombus (VTT), where the primary tumour invades the renal vein and inferior vena cava, affects 10-15% of renal cell carcinoma (RCC) patients. Curative surgery for VTT is high-risk, but ...
Despite several randomized controlled trials demonstrating the benefits of combination therapies for metastatic hormone-sensitive prostate cancer (mHSPC), a significant treatment gap persists. This ...
To provide evidence-based recommendations for patients with metastatic castration-resistant prostate cancer (mCRPC). An Expert Panel including patient representation completed a systematic review of ...